This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Wheeler, C. J. Articles by Yu, J. S. PubMed PubMed Citation Articles by Wheeler, C. J. Articles by Yu, J. S.

Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients

¹ Maxine Dunitz Neurosurgical Institute, Department of Neurosurgery, and ² Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California

Requests for reprints: Christopher J. Wheeler, 8631 West Third Street, Suite 800E, Los Angeles, CA 90048. Phone: 310-423-6646; Fax: 310-423-0302; E-mail: wheelerc{at}cshs.org.

Key Words: glioma • immunotherapy • vaccine

Cancer vaccine trials have failed to yield robust immune-correlated clinical improvements as observed in animal models, fueling controversy over the utility of human cancer vaccines. Therapeutic vaccination represents an intriguing additional therapy for glioblastoma multiforme (GBM; grade 4 glioma), which has a dismal prognosis and treatment response, but only early phase I vaccine trial results have been reported. Immune and clinical responses from a phase II GBM vaccine trial are reported here. IFN- responsiveness was quantified in peripheral blood of 32 GBM patients given therapeutic dendritic cell vaccines. Posttreatment times to tumor progression (TTP) and survival (TTS) were compared in vaccine responders and nonresponders and were correlated with immune response magnitudes. GBM patients (53%) exhibited 1.5-fold vaccine-enhanced cytokine responses. Endogenous antitumor responses of similar magnitude occurred in 22% of GBM patients before vaccination. Vaccine responders exhibited significantly longer TTS and TTP relative to nonresponders. Immune enhancement in vaccine responders correlated logarithmically with TTS and TTP spanning postvaccine chemotherapy, but not with initial TTP spanning vaccination alone. This is the first report of a progressive correlation between cancer clinical outcome and T-cell responsiveness after therapeutic vaccination in humans and the first tracing of such correlation to therapeutically exploitable tumor alteration. As such, our findings offer unique opportunities to identify cellular and molecular components of clinically meaningful antitumor immunity in humans. [Cancer Res 2008;68(14):5955–64]